Familial colorectal cancer history is associated with an altered immune–genomic profile in microsatellite-stable rectal cancer: a prospective multicentre cohort study
Silvia Negro, Monica Ortenzi(Marche Polytechnic University), Chiara Cipollari(La Salle University), Ivana Cataldo(Ospedale SS. Annunziata), Giovanni Bertalot(University of Trento), Melania Scarpa(University of Padua), Francesca Bergamo(Istituto Oncologico Veneto), Cesare Ruffolo(Ca' Foncello Hospital), Astghik Stepanyan(University of Padua), Marco Massani(AULSS 2 Marca Trevigiana), Alberto Brolese, Stefano Brignola(University of Padua), Tommaso Stecca(Ca' Foncello Hospital), Giorgio Rivella(University of Padua), Luca Dal Santo(University of Padua), Mario Gruppo(Istituto Oncologico Veneto), Pierluigi Pilati(Istituto Oncologico Veneto), Licia Laurino(University of Padua), Gaya Spolverato(University of Padua), Andromachi Kotsafti(Istituto Oncologico Veneto), Lavinia Ceccarini(Ospedale San Bassiano), Carlotta Ceccon(University of Padua), Luca Facci(University of Padua), Ottavia De Simoni(Istituto Oncologico Veneto), Marta Sbaraglia(University of Padua), Giovanni Pirozzolo(Ottawa Hospital), Mattia Barbareschi(University of Trento), Imerio Angriman, Boris Franzato(Istituto Oncologico Veneto), Emanuele Damiano Luca Urso, Laura Marinelli(Collaborative Group (United States)), Chiara Vignotto(University of Padua), Gaia Tussardi(Azienda Ospedale - Università Padova), Vincenza Guzzardo(University of Padua), Michele Antoniutti(Ca' Foncello Hospital), Anna Matteazzi(Azienda Ospedale - Università Padova), Luca Saadeh, Anna Pozza(AULSS 2 Marca Trevigiana), Sara Vedovato, Alfonso Recordare(Ospedale dell' Angelo), Isacco Maretto, Antonella D’Angelo, Roberta Salmaso, Valerio Pellegrini, Antonio Rosato, Matteo Zuin, Sara Lonardi, Giuseppe Portale, Francesca Galuppini, Quoc Riccardo Bao(University of Padua)
Cited by 0
Related Papers
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
A MicroRNA Targeting Dicer for Metastasis Control
|Cell|2010|665
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
|JAMA Oncology|2018|418